TP53 and primary central nervous system lymphoma: Few previous studies that report TP53 mutation status in PCNSL reveal incidences <10 % [10, 31], while, paradoxically, other investigations show higher incidences of p53 protein expression by immunhistochemistry (IHC) (29–60 %) as a surrogate marker of MUT-TP53 [3, 6].